Sponsor or institution
Clinical trials and research at Mirum Pharmaceuticals, Inc.
As of November 12, 2026, Find a Trial lists 5 clinical trials run by Mirum Pharmaceuticals, Inc. that are recruiting, at sites in 17 countries (most in Spain (4), France (3), Germany (3)). By phase: Phase 2 (1), Phase 3 (1), Phase 2/3 (1), Phase 4 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 5Clinical trials
- 17Countries
Newest trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Switching from bulevirtide to brelovitug for chronic hepatitis D treatment | Phase 2/3 | Graz and 45 other locations | Recruiting | Mar 6, 2026 |
| Long-term safety and outcomes of Livmarli for Alagille syndrome in the EU | Phase 4 | Brussels and 14 other locations | Recruiting | Dec 18, 2025 |
| MRM-3379 for males with Fragile X Syndrome (BLOOM) | Phase 2 | Phoenix, Arizona and 17 other locations | Recruiting | Oct 7, 2025 |
| Brelovitug versus bulevirtide for treating chronic hepatitis D (AZURE-2) | Phase 3 | Graz and 56 other locations | Recruiting | Oct 1, 2025 |
| Evaluating the long-term safety and outcomes of Livmarli in patients with liver diseases | — | Los Angeles, California and 7 other locations | Recruiting | Jan 5, 2024 |
All recruiting trials (5)
-
Switching from bulevirtide to brelovitug for chronic hepatitis D treatment
This trial tests whether switching people with chronic hepatitis D who are already taking bulevirtide to brelovitug keeps their infection under control and is safe.
-
Long-term safety and outcomes of Livmarli for Alagille syndrome in the EU
This study will follow people with Alagille syndrome who take Livmarli to see if it is safe, well tolerated over the long term, and continues to reduce cholestatic itching.
-
MRM-3379 for males with Fragile X Syndrome (BLOOM)
This trial will test three doses of the oral drug MRM-3379 in males with Fragile X Syndrome aged 16–45 (placebo-controlled), with a parallel open-label group for ages 13–15.
-
Brelovitug versus bulevirtide for treating chronic hepatitis D (AZURE-2)
This trial tests whether weekly brelovitug works better than daily bulevirtide followed by weekly brelovitug for adults with chronic hepatitis D who are on HBV nucleos(t)ide therapy.
-
Evaluating the long-term safety and outcomes of Livmarli in patients with liver diseases
This study is testing how safe and effective the medication Livmarli is for people with Alagille syndrome or Progressive familial intrahepatic cholestasis over a five-year period.
Quick answers
How many clinical trials run by Mirum Pharmaceuticals, Inc. are recruiting right now?
5, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 17 countries. The most sites are in Spain (4 trials), France (3 trials), Germany (3 trials), Italy (3 trials), United States (2 trials). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 2: 1, Phase 3: 1, Phase 2/3: 1, Phase 4: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.